Follow-up care over 12 months of patients with prostate cancer in Spain
A multicenter prospective cohort study

Xavier Bonfill, MD, PhD,a,b,c,d, María José Martínez-Zapata, MD, PhDa,b,e,f, Robin WM Vernooij, PhDb, María José Sánchez, MD, PhDg,h, María Morales-Suárez-Varela, MD, PhDh,i, José Ignacio Emparanza, MD, PhDj,k, Montse Ferrer, MD, PhDg,h, José Ignacio Pijoan, MD, PhDk,l, Joan Palou, MD, PhDk, Eva Madrid, MD, PhDk, Víctor Abraira, PhDm, Javier Zamora, PhDn,m,n, on behalf of the EMPARO-CU study group

Abstract
The therapeutic approach is crucial to prostate cancer prognosis. We describe treatments and outcomes for a Spanish cohort of patients with prostate cancer during the first 12 months after diagnosis and identify the factors that influenced the treatment they received.

This multicenter prospective cohort study included patients with prostate cancer followed up for 12 months after diagnosis. Treatment was stratified by factors such as hospital, age group (<70 and ≥70 years), and D'Amico cancer risk classification. The outcomes were Eastern Cooperative Oncology Group (ECOG) performance status, adverse events (AEs), and mortality. The patient characteristics associated with the different treatment modalities were analyzed using multivariate logistic regression.

We included 470 men from 7 Spanish tertiary hospitals (mean [standard deviation] age 67.8 [7.6] years), 373 (79.4%) of which received treatment (alone or in combination) as follows: surgery (n = 163; 34.7%); radiotherapy (RT) (n = 149; 31.7%); and hormone therapy (HT) (n = 142; 30.2%). The remaining patients (n = 97) were allocated to no treatment, that is, watchful waiting (14.0%) or active surveillance (5.7%). HT was the most frequently administered treatment during follow-up and RT plus HT was the most common therapeutic combination. Surgery was more frequent in patients aged <70, with lower histologic tumor grades, Gleason scores <7, and lower prostate-specific antigen levels; while RT was more frequent in patients aged ≥70 with histologic tumor grade 4, and higher Gleason scores. HT was more frequent in patients aged ≥70, with histologic tumor grades 3 to 4, Gleason score ≥8, ECOG ≥1, and higher prostate-specific antigen levels. The number of fully active patients (ECOG score 0) decreased significantly.
1. Introduction

Prostate cancer is the most common cancer in men in both Western Europe (over lung cancer, in second place) and in Spain, with an estimated incidence of 171.4 and 147.9 patients per 100,000 men per year, respectively. However, mortality for prostate cancer is relatively low in comparison with other malignancies. Prognosis depends not only on patient characteristics, but also on the ability of healthcare systems to timely detect and treat patients with prostate cancer.

Once diagnosed, patients are generally treated according to their performance status, clinical cancer stage, tumor characteristics, and—ideally—individual values and preferences. In addition to making recommendations to guide clinical management of prostate cancer patients, it is important to conduct studies that focus on how patients are treated in the real world and the association between their characteristics and the specific treatment modalities. Some initiatives have been recently developed in Asia in a cohort of patients with prostate cancer attending 7 tertiary hospitals in Spain: Hospital Universitario 12 de Octubre (Hospital A); Hospital Universitario Ramón y Cajal (Hospital B) in Madrid; Hospital Universitario Donostia (Hospital C) in Donostia-San Sebastián; Hospital General Universitario de Valencia (Hospital D) in Valencia; Hospital Universitario Virgen de las Nieves (Hospital E) in Granada; Fundación Puigvert-Hospital de la Santa Creu i Sant Pau (Hospital G) (co-ordinating center); and Hospital del Mar (Hospital F) in Barcelona. The protocol was approved by all centers’ Research Ethics Committees.

Patients with prostate cancer were consecutively enrolled from October 2010 to September 2011. Inclusion criteria were patients with histologically proven and newly diagnosed prostate cancer at any stage of the disease, who were being treated at any of the 7 participating hospitals, and who had provided their informed consent.

We collected the following data: age; body mass index; World Health Organization (WHO) histologic tumor grade (1–4)[7]; prostate-specific antigen (PSA) value at diagnosis; total Gleason score[8]; clinical cancer stage (I–IV); tumor stage (T/Tumor size) N (lymph Nodes ) M (Metastasis) Classification of Malignant Tumors Staging System)[9]; intervention, that is surgery, RT, hormone therapy (HT), or watchful waiting/active surveillance (defined as no treatment other than diagnostic tests such as rectal examination, prostatic ultrasound, biopsy, or PSA measurement); Eastern Cooperative Oncology Group (ECOG) performance status score; adverse events (AEs) based in the Common Terminology Criteria for Adverse Events[10] and mortality during follow-up.

Using TNM tumor stages, PSA values, and Gleason scores, we classified patients into the following D’Amico risk[11] groups: low risk (PSA 10 ng/mL, Gleason ≤ 6, and T1c-T2a); intermediate risk (PSA 10–20 ng/mL, Gleason 7, and T2b); and high risk (PSA >20 ng/mL, Gleason ≥8, and T2c-T3a). We stratified the analysis by age (<70 years and ≥70 years), initial treatment, D’Amico risk, hospital, and ECOG score.

We established the cut-off age at 70 years based on a national male life expectancy of 80 years[12] and the fact that clinical treatment guideline recommendations depend on whether the patient’s life expectancy is more or less than 10 years at the time of diagnosis.[13]

For the descriptive analyses, we used relative frequencies for categorical variables, and either mean and standard deviation or median and interquartile range for continuous variables, depending on the skewness of the data distribution.

The proportion of missing values for each variable is reported. To study baseline patient characteristics associated with specific treatment modalities, we used 3 independent multivariate logistic regression models. Each model had a binary outcome measure representing whether a patient received as first-line treatment the modalities: surgery (model 1), RT (model 2), or hormonal therapy (model 3). We performed a backward elimination strategy to fit the most final parsimonious model containing the clinical and demographic factors significantly associated to the odds of receiving each one of the treatment alternatives. At each iteration, we excluded a variable from the model when its P value was greater than .05, excluding first the variable with higher P value. The potential predictors included in the maximal model were selected based on clinical plausibility, and included age, body mass index, WHO histological tumor grade, TNM tumor stage, total Gleason score, and PSA value at diagnosis. We report the odds ratio and the corresponding 95% confidence interval. We used the non-parametric Friedman test for repeated measures to estimate ECOG within-patient change across follow-up assessments (i.e., baseline, 6 months, and 12 months). This
3. Results

In total, we recruited 470 patients: 451 (96.0%) of them completed the 12-month follow-up, 12 (2.6%) died, and 7 dropped out of the study (Fig. 1). The cause of death for 4 patients was prostate cancer progression; 2 died from other cause unrelated to cancer; and the cause was unknown for 1 patient. Mean (standard deviation) age was 67.8 (7.6) years, and 277 (58.9%) patients were under 70 years old (Table 1).

The most frequent WHO histological grades were 2 (n = 195; 41.5%) and 3/4 (n = 169; 36.0%). Most patients (62.5%) had T1b-T2b tumors. Over half of the patients (55.1%) scored ≤6 on the Gleason scale, 26.8% scored 7, and 15.7% scored ≥8 (Table 1).

After diagnosis, 97 patients (20.6%) were allocated to watchful waiting and 373 (79.4%) were treated as follows: surgery (n = 163; 34.7%); RT (n = 149; 31.7%); and HT (n = 142; 30.2%) (Table 1). Most patients treated with surgery were <70 years (83.4%) and had T1b-T2b tumor stage (66.3%). Among the patients treated with RT, 45% were ≥70 years, 67.1% had T1b-T2b tumor stage, and 12.8% had a Gleason score ≥8. Patients treated with HT were generally ≥70 years (57.7%), had higher Gleason scores (≥8; 30.3%); around half each had T1b-T2b and T2c-T4 tumor stages (50.7% and 46.5%, respectively) (Table 1).

Just under one fifth of patients (n = 87; 18.5%) received a combination of treatments, most frequently RT plus HT (n = 72; 15.3%) (Table 2). During the follow-up period, 165 patients (35.1%) underwent surgery, 164 (34.9%) received RT, and 193 (41.1%) received HT. By the end of this period, 27 patients (5.7%) allocated to watchful waiting at baseline were reallocated.

Bonfill et al. Medicine (2021) 100:47 www.md-journal.com
to active surveillance, and 66 (14.1%) continued in watchful waiting (Table 2).

While 75.3% of the patients had an ECOG score of 0 at baseline (Fig. 2), this percentage was observed to fall over time, with 69.3% scoring 0 at 6 months, and 65.1% scoring 0 at 12 months. Among the patients <70 years undergoing surgery, 41.2%, 30.9%, and 27.9% had low, intermediate, and high D’Amico risk, respectively.

### Table 1
Descriptive characteristics of patients by baseline treatment.

|                          | All patients N=470 | Surgery N=163 | Radiotherapy N=149 | Hormone therapy N=142 | Watchful waiting N=97 |
|--------------------------|--------------------|---------------|--------------------|------------------------|----------------------|
| Age                      |                    |               |                    |                        |                      |
| <70 yrs                  | 277 (58.9)         | 136 (83.4)    | 81 (54.4)          | 55 (38.7)              | 51 (52.6)            |
| ≥70 yrs                  | 182 (38.7)         | 25 (15.3)     | 67 (45.0)          | 82 (57.7)              | 42 (43.3)            |
| Missing data             | 11 (2.3)           | 2 (1.2)       | 1 (0.7)            | 5 (3.5)                | 4 (4.1)              |
| BMI                      |                    |               |                    |                        |                      |
| <25                      | 95 (20.2)          | 32 (19.8)     | 25 (16.7)          | 27 (19.0)              | 27 (27.8)            |
| 25–<30                   | 232 (49.4)         | 89 (54.6)     | 69 (46.3)          | 65 (47.8)              | 43 (44.3)            |
| ≥30                      | 125 (26.6)         | 36 (22.1)     | 49 (32.9)          | 46 (32.4)              | 23 (23.7)            |
| Missing data             | 18 (3.8)           | 6 (3.7)       | 6 (4.0)            | 4 (2.8)                | 4 (4.1)              |
| D’Amico risk             |                    |               |                    |                        |                      |
| Low                      | 169 (36.0)         | 66 (40.5)     | 61 (40.9)          | 26 (18.3)              | 33 (34.0)            |
| Intermediate             | 114 (24.3)         | 53 (32.5)     | 32 (21.5)          | 27 (19.0)              | 23 (23.7)            |
| High                     | 186 (39.6)         | 44 (27.0)     | 55 (36.9)          | 88 (62.0)              | 41 (42.3)            |
| Missing data             | 1 (0.1)            | 0             | 1 (0.7)            | 1 (0.7)                | 0                    |
| Histologic grade         |                    |               |                    |                        |                      |
| 1                        | 23 (4.9)           | 7 (4.3)       | 7 (4.7)            | 4 (2.8)                | 7 (7.2)              |
| 2                        | 195 (41.5)         | 87 (53.4)     | 61 (40.9)          | 46 (32.4)              | 31 (32.0)            |
| 3/4                      | 169 (36.0)         | 45 (27.6)     | 49 (32.9)          | 75 (52.8)              | 41 (42.3)            |
| Missing data             | 81 (17.7)          | 24 (14.7)     | 32 (21.5)          | 17 (11.9)              | 18 (18.6)            |
| Tumor stage              |                    |               |                    |                        |                      |
| Tx                       | 1 (0.2)            | 0             | 0                  | 1 (0.7)                | 0                    |
| T1a-c                    | 193 (41.1)         | 70 (42.9)     | 64 (43.0)          | 38 (26.8)              | 41 (42.3)            |
| T2a-c                    | 188 (40.0)         | 73 (44.8)     | 54 (36.2)          | 55 (38.7)              | 41 (42.3)            |
| T3a-b                    | 74 (15.7)          | 16 (9.8)      | 28 (18.8)          | 41 (28.9)              | 12 (12.4)            |
| T4                       | 8 (1.7)            | 0             | 0                  | 5 (3.5)                | 2 (2.1)              |
| Missing data             | 6 (1.3)            | 4 (2.5)       | 3 (2.0)            | 2 (1.4)                | 1 (1.0)              |
| Gleason grade            |                    |               |                    |                        |                      |
| 1 (<6)                   | 261 (55.1)         | 103 (63.2)    | 88 (59.1)          | 54 (38.0)              | 50 (51.5)            |
| 2 (7 = 3+4)              | 98 (20.9)          | 42 (25.8)     | 30 (20.1)          | 24 (16.9)              | 21 (21.6)            |
| 3 (7 = 4+3)              | 28 (6.1)           | 9 (5.6)       | 9 (6.0)            | 15 (10.6)              | 4 (4.1)              |
| 4 (8)                    | 42 (9.2)           | 3 (1.8)       | 14 (9.4)           | 24 (16.9)              | 12 (12.4)            |
| 5 (9, 10)                | 32 (6.8)           | 3 (1.8)       | 5 (3.4)            | 19 (13.4)              | 10 (10.3)            |
| Missing data             | 9 (1.9)            | 3 (1.8)       | 3 (2.0)            | 6 (4.2)                | 0                    |
| PSA                      |                    |               |                    |                        |                      |
| Median (IQR)             | 7.6 (7.8)          | 6.5 (4.4)     | 7.8 (7.8)          | 13.0 (14.4)            | 6.7 (5.2)            |

Eighty-seven patients received a combination of treatments. BMI = body mass index, IQR = interquartile range, PSA = prostate-specific antigen.

### Table 2
Treatment distribution at baseline per patient and during 12-month follow-up (N=470 patients).

| Treatment                          | Baseline n (%) | Follow-up<sup>a</sup> n (%) |
|------------------------------------|----------------|-----------------------------|
| Surgery                            | 151 (32.1)     | 3 (0.6)                     |
| Radiotherapy                       | 71 (15.1)      | 16 (3.2)                    |
| Hormone therapy                    | 66 (14.1)      | 49 (10.4)                   |
| Chemotherapy                       | 0              | 3 (0.6)                     |
| Other                              | 2 (0.4)        | 6 (1.3)                     |
| Surgery + radiotherapy             | 7 (1.5)        | 0                            |
| Surgery + hormone therapy          | 5 (1.1)        | 0                            |
| Radiotherapy + hormone therapy      | 71 (15.1)      | 2 (0.4)                     |
| Watchful waiting                   | 97 (20.6)      | 66 (14.1)                   |
| Active surveillance                | 0              | 27 (5.7)                    |
| Only baseline treatment            | –              | 299 (63.7)                  |

<sup>a</sup>Patients with new treatments during follow-up.
risk, respectively ($P = .027$); and among those receiving HT, 18.2%, 20.2%, and 61.8% had low, intermediate, and high risk, respectively ($P < .001$). In this age group there was no difference in the odds of patients receiving RT ($P = .098$) or being assigned to watchful waiting (0.748) (Table 3). Among the patients ≥70 years undergoing surgery, 32.0%, 44.0%, and 24.0% had low, intermediate, and high D’Amico risk, respectively ($P = .044$); among those receiving RT, 36.4%, 28.8%, and 34.8% had low, intermediate, and high risk, respectively ($P = .030$); and among those receiving HT, 17.3%, 18.5%, and 64.2% had low, intermediate, and high risk, respectively ($P < .001$). In this age group, there was no difference in the odds of patients being assigned to watchful waiting (0.756) (Table 3).

At baseline, the first-line treatments for patients with prostate cancer were surgery for hospitals C (51.4%), F (63.6%), and G (50.7%); RT for hospitals A (22.9%) and B (38.5%); and HT for hospitals D (42.3%) and E (50.0%). HT was the most prescribed treatment in the 12-month follow-up, although its use ranged from 5.5% in hospital B to 50% in hospital E.

The multivariate logistic regression analysis (Table 4) revealed that patients <70 years, with low tumor histologic grades, Gleason scores <7, and low PSA levels were more likely to undergo surgery as first-line treatment for prostate cancer. Patients with a histologic tumor grade 4 and higher ECOG scores were more likely to be treated with RT. Lastly, patients ≥70 years, with tumor grades 3 or 4, Gleason scores ≥8, ECOG scores ≥1, and higher PSA levels were most likely to be treated with HT.

A total of 230 AEs were reported, with 48.9% of patients experiencing at least one (Table 5). By intervention, the most frequent AEs were urinary incontinence (50.3%) and impotence.

### Table 3

| D’Amico risk | low | intermediate | high | \( P \) | low | intermediate | high | \( P \) |
|--------------|-----|-------------|------|--------|-----|-------------|------|--------|
|              | \( N = 277 \) | \( N = 115 \) | \( N = 68 \) | \( N = 94 \) | \( N = 49 \) | \( N = 46 \) | \( N = 86 \) | \( P \) |
| Surgery      | 56 (41.2) | 42 (30.9) | 38 (27.9) | .027 | 8 (32.0) | 11 (44.0) | 6 (24.0) | .044 |
| Radiotherapy | 36 (44.4) | 13 (16.1) | 32 (39.5) | .098 | 24 (36.4) | 19 (28.8) | 23 (34.8) | .030 |
| Hormone therapy | 10 (18.2) | 11 (20.2) | 34 (61.8) | <.001 | 14 (17.3) | 15 (18.5) | 52 (64.2) | <.001 |
| Watchful waiting | 23 (46.0) | 12 (24.0) | 15 (30.0) | .748 | 10 (23.3) | 11 (25.6) | 22 (51.2) | .756 |

Patients could receive more than 1 treatment. Percentages are calculated for rows. Data for 11 cases were missing for D’Amico risk.
for surgery; impotence (12.8%) and cystitis (12.8%) for RT; and hot flushes (26.1%), impotence (15.5), and reduced libido (14.8%) for HT. During the 12-month follow-up, 12 (2.6%) patients died.

4. Discussion

This prospective cohort study describes healthcare practices at 7 Spanish hospitals for newly diagnosed prostate cancer patients, focusing on primary therapy and patient-relevant clinical outcomes observed within the first 12 months since diagnosis. The majority of the 470 included patients were under 70 years old and 81% had localized prostate cancer. Primarily, surgery or RT were the initial treatment modalities for 1 in 3 patients, as per guideline recommendations.[3] HT was also administered in one third of patients as palliative treatment. During the 12-month follow-up, HT was the most frequent treatment and RT plus HT was the most frequent treatment combination.

One fifth of patients was assigned to watchful waiting after diagnosis, a similar rate to that reported by Hoffman et al[13] in a 6-month follow-up study. Our watchful waiting percentage decreased to 14% at 12-month follow-up, as the remaining 5.7% were moved to active surveillance. In contrast, Hoffman et al[13] described that more patients were in active surveillance at 18-month follow-up, while fewer than 2% remained in watchful waiting.

In our study a high proportion of patients with T1b-T2b tumor stage underwent surgery and received either RT or HT. A lower-than-expected proportion of patients with T2c-T4 tumor stage received RT or HT.

According to a recently published clinical trial, there is no single best treatment option for localized prostate cancer, as overall survival is similar for patients undergoing radical

### Table 4

|                      | Surgery OR (CI 95%) | P  | Radiotherapy OR (CI 95%) | P  | Hormone therapy OR (CI 95%) | P  |
|----------------------|--------------------|----|--------------------------|----|----------------------------|----|
| **Age (yrs)**        |                    |    |                          |    |                            |    |
| <70                  | 1 (Reference)      |    | 1 (Reference)            |    |                            |    |
| ≥70                  | 0.22 (0.13–0.38)   | <.001 | 2.17 (1.27–3.72)         | .005 |                            |    |
| **Histologic grade** |                    |    |                          |    |                            |    |
| ≤2                   | 1 (Reference)      |    | 1 (Reference)            |    |                            |    |
| 3                    | 1.08 (0.49–2.35)   | .851 | 0.84 (0.53–1.32)         | .450 |                            |    |
| 4                    | 0.21 (0.09–0.51)   | .001 | 1.90 (1.03–3.50)         | .040 |                            |    |
| **Gleason score**    |                    |    |                          |    |                            |    |
| ≤6                   | 1 (Reference)      |    | 1 (Reference)            |    |                            |    |
| 7                    | 1.08 (0.49–2.35)   | .842 | 1.02 (0.57–1.83)         | .938 |                            |    |
| ≥8                   | 0.08 (0.01–0.43)   | .003 | 4.24 (1.86–9.73)         | .001 |                            |    |
| **Log (PSA)**        | 0.53 (0.36–0.77)   | .001 | 3.17 (2.07–4.84)         | <.001 |                            |    |
| **ECOG score**       |                    |    |                          |    |                            |    |
| 0                    | 1 (Reference)      |    | 1 (Reference)            |    |                            |    |
| 1                    | 1.41 (0.85–2.32)   | .178 | 1.94 (1.06–3.56)         | .033 |                            |    |
| ≥2                   | 3.05 (0.99–9.37)   | .052 | 10.98 (1.91–63.1)        | .007 |                            |    |

CI = confidence interval, ECOG = Eastern Cooperative Oncology Group, OR = odds ratio, PSA = prostate-specific antigen.

### Table 5

| Adverse events by treatment through the 12-month follow-up period. |
|---------------------------------------------------------------|
| Surgery | Radiotherapy | Hormone therapy |
|---------|--------------|-----------------|
| N=163   | N=149        | N=142           |
| n (%)   | n (%)        | n (%)           |
| Urinary incontinence | 82 (50.3) | 19 (12.8) | 37 (26.1) |
| Urine frequency | 74 (45.4) | 19 (12.8) | 22 (15.5) |
| Urethral stricture | 5 (3.1) | 10 (6.7) | 21 (14.8) |
| Fecal incontinence | 2 (1.2) | 8 (5.4) | 6 (4.2) |
| Other | 10 (6.1) | 8 (5.4) | 5 (3.5) |
| Urinary incontinence | 8 (5.4) | 5 (3.4) | 4 (2.8) |
| Urinary incontinence | 21 (14.1) | 21 (14.1) | 3 (2.1) |
| Urinary incontinence | 12 (8.5) | 36 (20.4) | 2 (1.4) |
| Diarrhea | 2 (1.4) | 2 (1.4) | 1 (0.7) |
| Other | 12 (8.5) | 56 (39.4) |
prostatectomy, RT, or active surveillance.\textsuperscript{[14]} However, we found that certain factors influenced decision-making regarding different therapeutic options: patients who underwent surgery were younger and had better prognostic factors (lower histologic tumor grades, Gleason scores, and PSA levels); patients treated with RT had higher histological tumor grades and poorer ECOG scores; and lastly, patients who received palliative HT were older and had poorer prognostic factors (more advanced tumors, higher Gleason scores, higher PSA levels, and higher ECOG scores).

Other cohort studies have been published recently, but their results are not completely comparable to our study. These studies included prevalent and incident patients,\textsuperscript{[4,5]} and our study only focused on incident prostate cancer patients. One international multicenter cohort study focused on patients receiving RT.\textsuperscript{[4]} Twenty-seven percent of included patients underwent a prostatectomy before RT, whereas in our study the proportion was only 1.5%. The proportion of patients receiving RT and HT also differed between studies—69% and 15%, respectively. Another international multicenter cohort study included advanced prostate cancer, whereas our study mainly included localized prostate cancer.\textsuperscript{[3]}

While the Spanish National Health System is a public system providing universal coverage and free-of-charge treatments to patients, we found important differences in therapeutic choices between the 7 participating hospitals, with some preferring surgery, whereas others preferred RT or HT. This variability was probably related to patient characteristics and differing hospital criteria regarding treatments.

At baseline, 3 quarters of patients had a good performance status that worsened over the follow-up period. Only a small proportion of patients (2.6%) died during the first year, mainly due to cancer-related reasons. The most common AEs match those reported in previous studies,\textsuperscript{[14,15]} such as urinary incontinence and impotence for surgery, impotence\textsuperscript{[4]} and cystitis for RT, and hot flushes for HT.

Regarding limitations, our study may be affected by potential information bias, given that our data were prospectively obtained from hospital records and participants. However, we consider this limitation of little actual relevance.

A main strength of our study is that our patient sample is probably representative of the annual incident cases of patients diagnosed with prostate cancer in Spain, since they were recruited in 7 hospitals located in 5 different regions. In addition, the prospective nature of the study guarantees greater data consistency and accuracy, and so overcomes the typical shortcoming of retrospective data collection affecting similar studies carried out elsewhere. The relatively small number of patients lost to follow-up (4.2%) reinforces the validity of our results. A longer follow-up will undoubtedly be useful in further assessing the impact of diagnosis and therapy on prostate cancer patients.

5. Conclusion

Surgery and RT were the most common curative options used on initial diagnosis of prostate cancer. Watchful waiting was applied to 1 in 5 patients after diagnosis. Palliative HT was the most prescribed follow-up treatment. Surgery was more frequently indicated in younger patients with better prognostic factors. HT was more frequent in older patients, with more advanced tumor stages and higher Gleason scores. Around half of the patients experienced an AE related to the treatment. Performance status decreased steadily in the first year after diagnosis. The treatments administered by the participating hospitals varied widely.

Acknowledgments

Ailish Maher and Andrea Cervera Alepuz revised the English in a version of this manuscript. María José Martínez Zapata is funded by a Miguel Servet research contract (CPII20/00023).

EMPARO Study Group: Coordinating investigator: Xavier Bonfill Cosp (Iberoamerican Cochrane Centre, Public Health and Clinical Epidemiology Service, Hospital de la Santa Creu i Sant Pau, IIB Sant Pau, Barcelona, Spain).

Project manager: María José Martínez Zapata (Iberoamerican Cochrane Centre, IIB Sant Pau, Barcelona, Spain).

Clinical research assistants: Alborrada Martínez (Universidad de Valencia); Enrique Morales Olivera (Escuela Andaluza de Salud Pública, Granada, Spain); Esther Canovas, Laura Muñoz, Gemma Mas, René Acosta, Ekaterina Popova (Iberoamerican Cochrane Centre, IIB Sant Pau, Barcelona, Spain); Irma Opsina (Hospital 12 de Octubre, Madrid, Spain); María José Velázquez (Hospital Donostia, Donostia, Spain); Tamara Ruiz Merlo (Hospital Ramón y Cajal, Madrid, Spain); Gael Combarros Herman, Judit Tirado Muñoz (IMIM-Hospital del Mar Medical Research Institute, Barcelona, Spain).

Statistical analysis: Robin W.M. Vernooij (Iberoamerican Cochrane Centre, IIB Sant Pau, Barcelona, Spain); Javier Zamora and Claudia Coscia Requena (Hospital Ramón y Cajal, Madrid, Spain).

Co-investigators: Barcelona, Spain

Albert Frances (Hospital del Mar); Carola Orrego Villagran, Rosa Suñol (Instituto Universitario Avedis Donabedian); Dimelza Osorio, Gemma Sancho Pardo, Ignasi Bolívar, José Pablo Maroto, María Jesús Quintana, Cristina Martin (Hospital de la Santa Creu i Sant Pau); Ferran Algaba, Palou Redorta, Salvador Esquena (Fundació Puigvert); Jordi Bachs (Fundació Privada Hospital de la Santa Creu i Sant Pau); María José Martínez Zapata (Iberoamerican Cochrane Centre, IIB Sant Pau); Montserrat Ferrer Fores, Stephanie Schmidt, Olatz Garín, Virginia Becerra Bachito, Yolanda Pardo (IMIM-Hospital del Mar Medical Research Institute).

Bilbao, Spain

Amaia Martínez Galarza, José Ignacio Pijoán Zubizarreta (Hospital Universitario Cruces/BioCruces Health Research Institute).

Granada, Spain

Armando Suárez Pacheco, César García López, José Manuel Cozar Olmo (Hospital Universitario Virgen de las Nieves); Carmen Martínez, Daysy Chang Chan, María José Sánchez Pérez (Escuela Andaluza de Salud Pública).

Madrid, Spain

Ana Isabel Díaz Moratinos, Angel Montero Luis, Asunción Hervás, Carmen Vallejo Ocaña, Costantino Varona, Javier Burgos, Javier Zamora, Jose Alfredo Polo Rubio, Luis López-Fando Lavalle, Miguel Angel Jimenez Cidre, Muriel García, Alfonso, Nieves Plana Farras, Rosa Morera Lopez, Sonsoles Sancho Garcia, Victor Abraira, Victoria Gomez Dos Santos (Hospital Ramón y Cajal); Agustín Gómez de la Cámara, Javier de la Cruz, Juan Passas Martínez, Humberto García Muñoz, María Ángeles Cabeza Rodríguez (Hospital 12 de Octubre).

San Sebastián, Spain

Irene Ruiz Díaz, José Ignacio Emparanza, Juan Pablo Sanz Jaka (Hospital Universitario Donostia).
Valencia, Spain
Agustín Llopis González, María Morales (Universidad de Valencia); Carlos Camps, Cristina Caballero Díaz, Emilio Marqués Vidal, Francisco Sánchez Ballester, Joaquín Ulises Juan Escudero, Jorge Pastor Pedrero, José López Torrecilla, Maria Macarena Ramos Campos, Miguel Martorell Cebollada (Consortium Hospital General Universitario de Valencia).

Author contributions

Conceptualization: Xavier Bonfill.

Data curation: Maria Jose Martinez-Zapata.

Formal analysis: Robin WM Vernooij, Víctor Abraira, Javier Zamora.

Funding acquisition: Xavier Bonfill, Javier Zamora.

Investigation: Xavier Bonfill, Maria Jose Martinez-Zapata, María José Sánchez, María Morales-Suárez-Varela, José Ignacio Emparanza, Montse Ferrer, José Ignacio Pijoan, Joan Palou.

Methodology: Xavier Bonfill, Maria Jose Martinez-Zapata, Eva Madrid, Víctor Abraira, Javier Zamora.

Supervision: Xavier Bonfill, Maria Jose Martinez-Zapata.

Validation: Maria Jose Martinez-Zapata, Robin WM Vernooij.

Writing – original draft: Xavier Bonfill, Maria Jose Martinez-Zapata, Robin WM Vernooij, María Morales-Suárez-Varela, Eva Madrid, Javier Zamora.

Writing – review & editing: Xavier Bonfill, Maria Jose Martinez-Zapata, Robin WM Vernooij, María José Sánchez, María Morales-Suárez-Varela, José Ignacio Emparanza, Montse Ferrer, José Ignacio Pijoan, Joan Palou, Eva Madrid, Víctor Abraira, Javier Zamora.

References

[1] European Cancer Information System (ECIS). © European Union, 2018. Available at: https://ecis.jrc.ec.europa.eu. Accessed June 23, 2019.

[2] European Association Urology (EAU) guidelines. Edn. Presented at the EAU Annual Congress Copenhagen 2018. ISBN 978-94-92671-01-1.

[3] Sanda MG, Cadeddu JA, Kirkby E, et al. Clinically localized prostate cancer: AUA/ASTRO/SUO guideline. Part I: risk stratification, shared decision making, and care options. J Urol 2018;199:683–90.

[4] Seibold P, Webb A, Aguado-Barrera ME, et al. REQuITe: a prospective multicentre cohort study of patients undergoing radiotherapy for breast, lung or prostate cancer. Radiother Oncol 2019;138:59–67.

[5] Uemura H, Ye D, Kanesvaran R, et al. United in Fight against prOstate cancer (UFO) registry: first results from a large, multi-centre, prospective, longitudinal cohort study of advanced prostate cancer in Asia. BJU Int 2020;125:541–52.

[6] Bonfill X, Martinez-Zapata MJ, Vernooij RW, et al. Clinical intervals and diagnostic characteristics in a cohort of prostate cancer patients in Spain: a multicentre observational study. BMC Urol 2015;15:60.

[7] Eble JN, Sauter G, Epstein JL et al (Eds.). World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. Lyon: IARC Press; 2004.

[8] Epstein JL, Alsbrook W, Amin MB, Egevad LL. ISUP Grading CommitteeThe 2005 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma. Am J Surg Pathol 2005;29:1228–42.

[9] American Joint Committee on Cancer: AJCC Cancer Staging Manual. 6th ed. New York, NY: Springer; 2002. 335–340.

[10] Therapy evaluation program, common terminology criteria for adverse events, Version 4.0, DCTD, NCI, NIH, DHHS. June 3, 2010.

[11] D’Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998;279:969–74.

[12] Instituto Nacional de Estadística (INE), Spain 2018. Mujeres y hombres en España/Salud/4.1 Esperanza de vida. Available at: http://www.ine.es/sa/Satellite?c=INESeccion_CxP&c1=12547351106722&pagename=ProductosServicios%2FPPYSLayout&ccid=1259926380048&L=1. Accessed June 23, 2019.

[13] Hoffman KE, Niu J, Shen Y, et al. Physician variation in management of low-risk prostate cancer: a population-based cohort study. JAMA Intern Med 2014;174:1450–9.

[14] Hamdy FC, Donovan JL, Lane JA, et al. 10-Year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med 2016;375:1415–24.

[15] Wilt TJ, Jones KM, Barry MJ, et al. Follow-up of prostatectomy versus observation for early prostate cancer. N Engl J Med 2017;377:132–42.